Diabetes Mellitus, Type 2 Clinical Trial
Official title:
Effect of the Weekly Administration of Exenatide LAR or Dulaglutide on the Variability of Blood Pressure and Heart Rate of 24 Hours in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment.
Mortality due to cardiovascular problems is increased by having Diabetes Mellitus type 2
(DM2), related to the time of evolution and glucose levels or if alterations in blood
pressure coexist. With this variability there is greater damage to the target organ and in
patients with DM2 the process is more severe and frequent due to alterations in the
coagulation mechanisms that accelerate in the presence of hypertension, figures ≥135 / 85
mmHg are considered risk factors to develop coronary, cerebral or renal events. As a
quantitative range, blood pressure is currently monitored ambulatory by (MAP) which is the
most used and reliable non-invasive instrument for its evaluation. The American Association
of Clinical Endocrinologists (AACE) proposes an algorithm that contemplates initiating
management to patients with a diagnosis of diabetes with drugs such as metformin,
thiazolidinediones and glucagon-like peptide analogues type 1 (GLP1).
Exenatide LAR and Dulaglutide are GLP-1 analogue drugs with potential to decrease the
progressive losses of pancreatic β cell function and mass and cardiovascular risk (CV)
factors with maintained use, in addition to hypoglycemic, hypotensive effects, weight
decreases and visceral adiposity, however, it has been reported that although they share the
same basic mechanism of action, each one has a different molecular structure and
pharmacokinetic profile that make their pharmacological and clinical effects different, in
particular as regards the variability of blood pressure and heart rate.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | November 30, 2021 |
Est. primary completion date | November 30, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 31 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Patients both sexes - Age between 31 and 60 years - Diagnosis of diabetes according ADA criteria: (Fasting blood glucose levels >125 mg/dl or postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose > 200 mg/dl, or glycosylated hemoglobin >6.5%). • Informed consent signed Exclusion Criteria: - Women with confirmed or suspected pregnancy - Women under lactation and/or puerperium - Hypersensibility to ingredients of intervention - Physical impossibility for apply the drug - Known pancreatic, renal, hepatic, heart or thyroid diseased - Hypertension diagnosis - Previous treatment for glucose - Body Mass Index =39.9 kg/m2 - Triglycerides =500 mg/dL - Total cholesterol =300 mg/dL - Night or rotating shift workers - Blood Pressure =140/90 mmHg |
Country | Name | City | State |
---|---|---|---|
Mexico | Instituto de terapeutica Experimental y Clinica. Centro universitario de Ciencias de la Salud. Universidad de Guadalajara | Guadalajara | Jalisco |
Lead Sponsor | Collaborator |
---|---|
University of Guadalajara |
Mexico,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Heart rate: nighttime, daytime and 24-h | heart rate variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 h by oscillometric method Microlife WatchBP O3 | Baseline to Week 4 | |
Primary | Systolic blood pressure, daytime, night and 24 h | Blood pressure variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 h by oscillometric method Microlife WatchBP O33. | Baseline to Week 4 | |
Primary | Diastolic blood pressure, daytime, night and 24 h | Blood pressure variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 h by oscillometric method Microlife WatchBP O3 | Baseline to Week 4 | |
Primary | Blood pressure | Blood pressure will be measured at baseline and week 4 with a digital sphygmomanometer and the entered values reflect the blood pressure. | Baseline to Week 4 | |
Secondary | Categories: dipper o non dipper | Blood pressure variability will be evaluated with ambulatory blood pressure monitoring (ABPM) for 24 hrs by oscillometric method Microlife WatchBP O3 | Baseline to Week 4 | |
Secondary | Fasting glucose levels | The fasting glucose levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques and the entered values reflect the fasting glucose level at week 4 | Baseline to Week 4 | |
Secondary | Central and peripheral blood pressure | To determine and compare the effect of administration of Exenatide LAR or Dulaglutide on Central and peripheral blood pressure through HEM will be evaluated at baseline and week 4. | Baseline to Week 4 | |
Secondary | Pulse wave velocity | To determine and compare the effect of administration of Exenatide LAR or Dulaglutide on pulse wave velocity through VP1000-plus with Ankle-Brachial Index will be evaluated at baseline and week 4. | Baseline to Week 4 | |
Secondary | Cardio-ankle Vascular Index (CAVI) | To determine and compare the effect of administration of Exenatide LAR or Dulaglutide on arterial stiffness through Cardio-ankle Vascular Index (CAVI) will be evaluated at baseline and week 4. | Baseline to Week 4 | |
Secondary | Glycosylated hemoglobin | Glycosylated hemoglobin will be evaluated at baseline and week 4 by high pressure liquid chromatography (HPLC) and the entered values reflect the glycosylated hemoglobin at week 4 | Baseline to Week 4 | |
Secondary | Body Weight | The body weight will be measured at baseline and week 4 with a bioimpedance balance and the entered values reflect the body weight at week 4 | Baseline to Week 4 | |
Secondary | Body Mass Index | Body Mass Index will be calculated at baseline and week 4 with the Quetelet index formula and the entered values reflect the body mass index at week 4 | Baseline to Week 4 | |
Secondary | Total cholesterol | Total cholesterol levels will be evaluated at baseline and week 4 by enzymatic/colorimetric techniques and the entered values reflect the total cholesterol level at week 4 | Baseline to Week 4 | |
Secondary | Triglycerides levels | Triglycerides levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques and the entered values reflect the triglycerides level at week 4 | Baseline to Week 4 | |
Secondary | High density lipoprotein (c-HDL) levels | c-HDL levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques and the entered values reflect the c-HDL level at week 4 | Baseline to Week 4 | |
Secondary | Alanine aminotransferase (ALT) levels | ALT levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques | Baseline to Week 4 | |
Secondary | Aspartate aminotransferase (AST) levels | AST levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques [Time Frame: Baseline to Week 4 | Baseline to Week 4 | |
Secondary | Creatinine levels | Creatinine levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques | Baseline to Week 4 | |
Secondary | Uric acid levels | Uric acid levels will be evaluated at baseline and week 4 with enzymatic/colorimetric techniques | Baseline to Week 4 | |
Secondary | Waist Circumference | Waist circumference will be evaluated at baseline and at week 4 with a flexible tape | Baseline, week 4 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |